What is Rigel?
Founded in 1996 and headquartered in San Francisco, Rigel Pharmaceuticals operates at the intersection of biotechnology and clinical innovation. The company specializes in the discovery and development of small-molecule drugs, specifically targeting autoimmune diseases, muscle disorders, and inflammatory conditions. By maintaining a robust R&D infrastructure, Rigel has positioned itself as a critical player in the life sciences ecosystem, bridging the gap between early-stage scientific discovery and commercial-grade therapeutic application. Its market position is defined by a commitment to addressing unmet medical needs through precision medicine and advanced molecular research.
How much funding has Rigel raised?
Rigel has raised a total of $888.4M across 12 funding rounds:
Stock Offering
$127.5M
Stock Offering
$101.5M
Stock Offering
$140.5M
Stock Offering
$135.7M
Stock Offering
$46M
Stock Offering
$69.7M
Stock Offering
$58.4M
Debt
$60M
Stock Issuance/Offering (2008): $127.5M backed by Undisclosed
Stock Issuance/Offering (2009): $101.5M with participation from Undisclosed
Stock Issuance/Offering (2011): $140.5M led by Undisclosed
Stock Issuance/Offering (2012): $135.7M supported by Undisclosed
Stock Issuance/Offering (2017): $46M featuring Undisclosed
Stock Issuance/Offering (2017): $69.7M backed by Undisclosed
Stock Issuance/Offering (2018): $58.4M with participation from Undisclosed
Debt (2019): $60M led by MidCap Financial
Key Investors in Rigel
MPM Capital
MPM BioImpact manages early-stage venture funds, private/public impact funds and a public equities fund. We convert science into therapeutics to reach the patients that need them most.
Alta Partners
Alta Partners is a prominent venture capital firm specializing in healthcare and life sciences, dedicated to supporting entrepreneurs in building impactful companies since 1996.
Novartis
Novartis is a global pharmaceutical manufacturer headquartered in Switzerland, specializing in developing and producing innovative medications and healthcare solutions.
What's next for Rigel?
Looking ahead, Rigel Pharmaceuticals is poised to leverage its recent capital injection to accelerate its clinical trial milestones and expand its therapeutic portfolio. The strategic focus remains on optimizing the development lifecycle of its lead candidates, ensuring that the transition from laboratory research to patient-facing treatment is both efficient and scalable. As the company continues to refine its internal pipeline, it will likely prioritize partnerships with global pharmaceutical entities to enhance its distribution capabilities and market reach. The ongoing support from institutional investors provides the necessary financial runway to navigate the inherent risks of drug development while maintaining a competitive edge in the rapidly evolving landscape of autoimmune and inflammatory disease treatment.
See full Rigel company page
